Publications by authors named "Samantha Carriero"

Article Synopsis
  • Organophosphoate (OP) chemicals inhibit the enzyme acetylcholinesterase (AChE), making it challenging to study OP poisoning due to animals' natural resistance from serum carboxylesterase.
  • * A new genetically modified mouse strain, KIKO, was created to lack serum carboxylase and to express a human-like AChE protein, providing a better model for OP research.
  • * In the study, KIKO mice showed increased acetylcholine levels after OP exposure, and the presence of a reactive countermeasure in the brain was detected, highlighting the potential of these mice for developing OP antidotes.*
View Article and Find Full Text PDF

The addition of supplemental diets to laboratory animals, specifically rodents, is a common practice for the provision of additional nutritional support. We set out to investigate whether the use of commercially available supplemental diets during breeding affected fertility rate, litter size, pup health, and pup survival. Genetically modified female breeding mice with a C57BL/6 background were divided into 3 groups ( = 16 per group) that received standard rodent chow alone or standard rodent chow with one of 2 commercially available supplemental diets: Love Mash (Bio-Serv) extruded pellet or Nutra-Gel (Bio-Serv) diet gel.

View Article and Find Full Text PDF

TYK2 is a key mediator of IL12, IL23, and type I interferon signaling, and these cytokines have been implicated in the pathogenesis of multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, lupus, and inflammatory bowel diseases. Supported by compelling data from human genome-wide association studies and clinical results, TYK2 inhibition through small molecules is an attractive therapeutic strategy to treat these diseases. Herein, we report the discovery of a series of highly selective pseudokinase (Janus homology 2, JH2) domain inhibitors of TYK2 enzymatic activity.

View Article and Find Full Text PDF

TYK2 is a member of the JAK family of kinases and a key mediator of IL-12, IL-23, and type I interferon signaling. These cytokines have been implicated in the pathogenesis of multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, lupus, and inflammatory bowel diseases. Supported by compelling data from human genetic association studies, TYK2 inhibition is an attractive therapeutic strategy for these diseases.

View Article and Find Full Text PDF